In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center.
- Author:
Seong Ho CHOI
1
;
Mi Young AHN
;
Jin Won CHUNG
;
Mi Kyung LEE
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Doripenem; Gram-negative bacteria; Bacteremia
- MeSH: Adult; Amikacin; Anti-Infective Agents; Bacteremia; Carbapenems; Diffusion; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Pneumonia; Tertiary Care Centers*; Tertiary Healthcare*
- From:Infection and Chemotherapy 2015;47(3):175-180
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Doripenem is the most recently introduced antimicrobial agent of the carbapenem class. It is a valuable therapeutic option in the context of increasing antimicrobial resistance to imipenem and meropenem among gram-negative bacilli (GNB) clinical isolates. However, clinicians are usually reluctant to prescribe doripenem, because susceptibility to doripenem is not automatically reported by most clinical laboratories and the in vitro activity of doripenem against clinically significant GNB isolates remains uncertain. MATERIALS AND METHODS: We investigated the in vitro antibacterial activity of doripenem in GNB blood isolates in a tertiary care center. Over a period of 10 months, 212 adult bacteremia cases were treated at the study hospital. Doripenem susceptibility testing was performed for the 212 blood isolates by the disk diffusion method, and clinical data were collected. RESULTS: Among the blood isolates, the rate of doripenem resistance (7.5%) was lower than that of imipenem (12.9%) or other anti-GNB antimicrobial agents, except amikacin (2.1%). Almost all imipenem-susceptible GNB blood isolates (181/182, 99.5%) were susceptible to doripenem. Whereas doripenem resistance was rarely observed in Enterobacteriaceae (2/181, 1.1%), it was frequently observed in patients with non-fermentatative GNB (12/27, 44.4%), hospital-acquired infections (7/27, 25.9%), and pneumonia (11/49, 22.4%). CONCLUSION: Doripenem exhibited more potent in vitro activity against GNB blood isolates than other anti-GNB antimicrobial agents in a tertiary care center where it was infrequently prescribed compared with other carbapenems. However, its clinical utility may be limited due to the increasing number of carbapenem-resistant non-fermentative GNB infections.
